Experts warn about online testosterone marketing. Read why symptoms need assessment, repeat testing matters and supplement risks require careful distinction.
On 14 October 2026, The Mirror reported a warning raised in The BMJ by Professor Eric Kilpatrick and Professor Stephen Atkin about online promotion of testosterone treatment for symptoms such as fatigue and low mood.
This article is for informational purposes only. It is not medical advice and does not replace assessment by a qualified clinician.
According to The Mirror, Kilpatrick of Wythenshawe Hospital and Atkin of RCSI Medical University of Bahrain raised concerns about the growth of private and online testosterone clinics. Their warning focused on heavy promotion through social media and influencers as well as outdoor advertising.
The central issue is the route from a common symptom to a potentially long-term prescription. The authors warned that rapid-access subscription models may lead to unnecessary lifelong treatment and add to the NHS monitoring burden.
Their argument does not dismiss testosterone deficiency. It calls for a clearer distinction between symptoms that deserve investigation and evidence that supports a hormone diagnosis.
The Mirror's account identifies reduced libido and erectile dysfunction as possible features of testosterone deficiency. It also lists fatigue and reduced energy alongside depressive symptoms. These concerns matter even when their cause is uncertain.
However, the report says that the same complaints can have explanations other than testosterone deficiency. The authors identified obesity, medication, sleep apnoea and depression as possible contributors that should be assessed before lifelong therapy.
This distinction puts persistent fatigue into a wider clinical context. A symptom can justify a discussion about health without establishing which treatment is appropriate.
The report also relays the authors' view that obesity-related “pseudo-hypogonadism” may respond better to weight loss than testosterone treatment. That is a stated clinical point about assessing the cause. It is not a prediction about what will happen for any individual man.
The Mirror reports that the experts warned unnecessary testosterone use can suppress the body's own hormone production and impair fertility. They also raised concerns about blood clots and heart problems as well as mood disorders.
These concerns make the indication for treatment important. In the authors' account, a prescription should follow an assessment of whether testosterone deficiency explains the clinical picture. It should not simply follow recognition of symptoms used in advertising.
MedicalXpress's coverage of the same warning adds that treating men with nonspecific symptoms or borderline results creates greater uncertainty about benefits and long-term risks. That concern is especially relevant when marketing makes the treatment decision sound straightforward.
The useful question is therefore broader than whether testosterone might change a laboratory result. It is whether the proposed treatment addresses an established clinical problem and whether its expected benefits justify its risks.
The European Association of Urology guideline provides the diagnostic benchmark. It says late-onset hypogonadism requires compatible symptoms together with biochemical evidence of low morning testosterone on two or more occasions. It recommends repeat testing before treatment.
This combines two kinds of information: the man's clinical presentation and the laboratory evidence. Neither a symptom list nor a single result supplies the full assessment described by the guideline.
The role of confirmatory blood testing is therefore more than administrative. It is part of deciding whether the proposed diagnosis is supported.
The Endocrine Society also states that evidence does not support population-level testosterone screening of asymptomatic men. That position concerns blanket screening without symptoms. It does not argue against appropriate evaluation when relevant symptoms or clinical signs are present.
The Mirror reported that NHS testosterone prescriptions rose 52% from 2020/21 to 2024/25. The authors' warning appeared against that background and the reported expansion of private and online services.
The distinction between growth and appropriateness matters. The clinical question remains whether each diagnosis is supported and whether the proposed treatment fits the patient's circumstances.
In that sense, the prescription figure explains why the discussion attracts attention. The diagnostic guidance explains what should govern an individual assessment.
The coverage describes an expert warning rather than results from a new treatment trial. It raises important questions about diagnosis and prescribing. Its scope needs to remain clear when interpreting the headlines.
The Mirror's account does not quantify how frequently the listed adverse outcomes occur among men receiving testosterone. It also does not establish that every treated man will experience them.
The reported concerns should therefore be described as concerns about unnecessary treatment. They should not be converted into a claim that all testosterone therapy is harmful or that treatment is inappropriate for men with a confirmed indication.
The reported rise concerns NHS prescriptions. The Mirror says private prescriptions are not recorded nationally, so the available figures do not provide a complete count across public and private care.
The prescription increase also does not show how many men had confirmed deficiency. It cannot establish how many prescriptions were inappropriate or how many men were harmed. Using the figure as proof of overdiagnosis would go beyond the evidence presented.
The Mirror contrasted commercial claims that up to 30% of men over 40 have low testosterone with a clinical estimate of around 2% of men aged 40 to 79 having a genuine deficiency.
The article did not provide the underlying studies or the methods behind the commercial claims. The age descriptions also differ. These figures should not be treated as a direct calculation of how much any company exaggerates prevalence.
For readers, the important distinction is between a broad marketing claim and the diagnostic criteria used in clinical care. A population claim does not establish the cause of one person's symptoms.
The Mirror's wording moves between “supplements” and testosterone treatment. Its discussion also concerns prescribing services and medication. That makes product identification essential to interpreting the warning.
Over-the-counter products, unregulated products and prescribed testosterone therapy should remain distinct. The report does not establish that their ingredients or risks are interchangeable. In particular, the reported effects on natural hormone production should not be assigned to every product sold as a testosterone supplement.
This is also why evaluating supplement claims separately matters. A shared marketing term does not make products medically equivalent.
The Mirror says it is unclear how consistently private clinics use repeated testing. It does not provide an audit showing the proportion that follow or depart from diagnostic guidance.
The warning supports asking about a service's assessment process. It does not support a blanket conclusion that private providers skip confirmation or that rapid access alone proves poor care.
The immediate clinical message is reinforcement rather than a change in practice. The reported warning does not introduce a new diagnostic rule. The EAU guideline already calls for compatible symptoms and confirmed low morning results before diagnosis and treatment.
For men assessing an online offer, the practical focus is the reasoning behind the proposed care. The research supports questions such as:
These are questions for a qualified clinician rather than a checklist for self-diagnosis. They help distinguish an assessment from a sales message without assuming that any particular provider has failed to meet clinical standards.
A service advertising rapid treatment from broad symptoms or a single result warrants clarification about its diagnostic process. That means understanding whether it evaluates other causes and arranges confirmation. The evidence supports seeking that explanation rather than judging care by convenience or promotional confidence.
Persistent symptoms should not be dismissed as ordinary ageing simply because they are common. Equally, their presence should not be treated as proof that testosterone is the missing treatment. The appropriate response is an assessment that takes both symptoms and laboratory findings seriously.
The bottom line is that this warning should not immediately change established diagnostic practice. It strengthens the case for following it. Decisions about starting or changing prescribed treatment remain individual clinical decisions rather than conclusions to draw from a headline.
A clinician leads the assessment of fatigue or changes in libido; Testostra supports understanding through evidence-led education rather than personal treatment advice. Its coverage connects symptom uncertainty with clear explanations of testing and TRT so men have context for a clinical conversation without being assigned a diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra